JP2023543218A5 - - Google Patents

Info

Publication number
JP2023543218A5
JP2023543218A5 JP2023518775A JP2023518775A JP2023543218A5 JP 2023543218 A5 JP2023543218 A5 JP 2023543218A5 JP 2023518775 A JP2023518775 A JP 2023518775A JP 2023518775 A JP2023518775 A JP 2023518775A JP 2023543218 A5 JP2023543218 A5 JP 2023543218A5
Authority
JP
Japan
Prior art keywords
expression
repressor
dna sequence
binding
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051945 external-priority patent/WO2022067033A1/en
Publication of JP2023543218A publication Critical patent/JP2023543218A/ja
Publication of JP2023543218A5 publication Critical patent/JP2023543218A5/ja
Pending legal-status Critical Current

Links

JP2023518775A 2020-09-24 2021-09-24 遺伝子発現を阻害するための組成物及び方法 Pending JP2023543218A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063082555P 2020-09-24 2020-09-24
US63/082,555 2020-09-24
US202163242957P 2021-09-10 2021-09-10
US63/242,957 2021-09-10
PCT/US2021/051945 WO2022067033A1 (en) 2020-09-24 2021-09-24 Compositions and methods for inhibiting gene expression

Publications (2)

Publication Number Publication Date
JP2023543218A JP2023543218A (ja) 2023-10-13
JP2023543218A5 true JP2023543218A5 (cg-RX-API-DMAC7.html) 2024-10-02

Family

ID=80845810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518775A Pending JP2023543218A (ja) 2020-09-24 2021-09-24 遺伝子発現を阻害するための組成物及び方法

Country Status (7)

Country Link
US (1) US20230399640A1 (cg-RX-API-DMAC7.html)
EP (1) EP4217477A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023543218A (cg-RX-API-DMAC7.html)
KR (1) KR20230074525A (cg-RX-API-DMAC7.html)
AU (1) AU2021350024A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023003424A (cg-RX-API-DMAC7.html)
WO (1) WO2022067033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2018049075A1 (en) 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US20250236854A1 (en) * 2021-10-05 2025-07-24 Glaxosmithkline Intellectual Property Development Limited GSK Medicines Research Centre Crispr/cas9-based fusion proteins for modulating gene expression and methods of use
WO2024040254A2 (en) * 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
KR20250128349A (ko) * 2022-12-23 2025-08-27 에피제닉 테라퓨틱스 피티이 리미티드 융합체 및 이의 용도
JP2026518711A (ja) 2023-05-16 2026-06-09 フラッグシップ ラブズ 114, インコーポレイテッド 標的遺伝子のメチル化を調節するための方法及び組成物
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
WO2025064469A1 (en) * 2023-09-18 2025-03-27 Omega Therapeutics, Inc. Methods for assessing dosage for epigenetic modifying agents
WO2025171047A1 (en) * 2024-02-05 2025-08-14 Bioventures, Llc Leveraging cancer-evolved resistance mechanisms to enhance ezh2 activity in adoptive t cells
WO2025261475A1 (zh) * 2024-06-21 2025-12-26 益杰立科(上海)生物科技有限公司 靶向血管内皮生长因子的工程化基因转录阻抑工具及用途
WO2026064556A1 (en) * 2024-09-19 2026-03-26 Arc Research Institute Epigenetic modulation system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
GB201418965D0 (cg-RX-API-DMAC7.html) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
AU2016308339A1 (en) * 2015-08-18 2018-04-12 Baylor College Of Medicine Methods and compositions for altering function and structure of chromatin loops and/or domains
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
EP3867368A4 (en) * 2018-10-15 2022-08-10 Flagship Pioneering Innovations V, Inc. DESTROYING THE ASSEMBLY OF A GENOMIC COMPLEX IN FUSION GENES
WO2020160125A1 (en) * 2019-01-29 2020-08-06 Flagship Pioneering Innovations V, Inc. Compositions comprising an endonuclease and methods for purifying an endonuclease

Similar Documents

Publication Publication Date Title
US12246061B2 (en) Sequence specific antimicrobials
Langley et al. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents
Dai et al. Classical HDACs in the regulation of neuroinflammation
Glajch et al. Epigenetic mechanisms involved in Huntington's disease pathogenesis
JP2022527108A5 (cg-RX-API-DMAC7.html)
Sinha et al. PARP1-modulated chromatin remodeling is a new target for cancer treatment
Rojewska et al. PD98059 influences immune factors and enhances opioid analgesia in model of neuropathy
HUP9902103A2 (hu) Triarilvegyületek
EP3632901A1 (en) Histone acetyltransferase activators and uses thereof
CN103763921B (zh) 组蛋白乙酰转移酶激活剂的用途
PH12022552237A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
Hurst Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes
PH12022552238A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP2022512974A5 (cg-RX-API-DMAC7.html)
JP2023543056A5 (cg-RX-API-DMAC7.html)
MX2022012844A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
CA3193868A1 (en) Compositions and methods for inhibiting the expression of multiple genes
JP5788907B2 (ja) 疾患の治療に使用される化合物
CN118681022A (zh) 治疗高毒力肺炎克雷伯菌感染的方法
Urnov et al. Chromatin organisation and human disease
JP7153947B2 (ja) 口腔の炎症の治療のために用いられるイヌicam-1に対するアンチセンス薬物
JP2002512029A5 (cg-RX-API-DMAC7.html)
WO2023288240A8 (en) Antisense oligonucleotide (aso) gene inhibition and treatment
EP4595976A1 (en) Composition for treating cancer containing histone deacetylase inhibitor, and anticancer adjuvant for cancer immunotherapy
US20040265286A1 (en) Method of lethally sensitizing human and animal cells